Company: SXTPW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-043779
Chunk: 41

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 41
---
 Delaware that provides for a 1-for-12 split. On February 24, 2025, we effectuated
a 1-for-5 reverse stock split of our common stock (the “1:5 Reverse Stock Split”). Beginning February 24, 2025, our common
stock traded on The Nasdaq Capital Market on a split adjusted basis.

As a result of the 1:5 Reverse Stock Split, proportional
adjustments were made to the number of shares of common stock issuable upon exercise or conversion of our equity awards, warrants, and
other equity instruments convertible into common stock, as well as the respective exercise prices, if applicable in accordance with the
terms of the instruments. No fractional shares of common stock were issued in connection with the 1:5 Reverse Stock Split and all fractional
shares were rounded up to the nearest whole share with respect to outstanding shares of common stock. Unless otherwise noted, all references
to numbers of shares of our common stock and per share information presented in this Quarterly Report on Form 10-Q have been retroactively
adjusted to reflect the effects of the 1:5 Reverse Stock Split.

January 2025 Offering

On January 28, 2025, we entered into a securities
purchase agreement (the “January 2025 Securities Purchase Agreement”) with certain institutional investors (the “January
2025 Purchasers”) pursuant to which we sold an aggregate of 204,312 shares of common stock at a purchase price of $5.105 per share
in a registered direct offering priced at-the-market under the rules of The Nasdaq Stock Market LLC (“Nasdaq”). In a concurrent
private placement, we also issued to the January 2025 Purchasers unregistered warrants (the “January 2025 Warrants”) to purchase
up to an aggregate of 408,621 shares of common stock at an exercise price of $3.855 per share. The January 2025 Warrants are exercisable
upon issuance and expire twenty-four months from the date of issuance.

The shares were offered pursuant to a “shelf”
registration statement on Form S-3 (Registration No. 333-280796), which was declared effective by the Securities and Exchange Commission
(the “SEC”) on July 18, 2024 as supplemented by a prospectus supplement dated January 28, 2025, filed with the SEC on January
30, 2025, and accompanying base prospectus, pursuant to Rule 424(b)(5) prom